المؤلفون: Jones, Robin L., Chawla, Sant P., Attia, Steven, Schöffski, Patrick, Gelderblom, Hans, Chmielowski, Bartosz, Le Cesne, Axel, Van Tine, Brian A., Trent, Jonathan C., Patel, Shreyaskumar, Wagner, Andrew J., Chugh, Rashmi, Heyburn, John W., Weil, Susan C., Wang, Wenquan, Viele, Kert, Maki, Robert G.

مصطلحات موضوعية: MORAb‐004, endosialin, ontuxizumab, sarcomas, tumor endothelial marker 1 (TEM‐1), Public Health, Oncology and Hematology, Health Sciences

وصف الملف: application/pdf

العلاقة: Jones, Robin L.; Chawla, Sant P.; Attia, Steven; Schöffski, Patrick; Gelderblom, Hans; Chmielowski, Bartosz; Le Cesne, Axel; Van Tine, Brian A.; Trent, Jonathan C.; Patel, Shreyaskumar; Wagner, Andrew J.; Chugh, Rashmi; Heyburn, John W.; Weil, Susan C.; Wang, Wenquan; Viele, Kert; Maki, Robert G. (2019). "A phase 1 and randomized controlled phase 2 trial of the safety and efficacy of the combination of gemcitabine and docetaxel with ontuxizumab (MORAb‐004) in metastatic soft‐tissue sarcomas." Cancer (14): 2445-2454.; http://hdl.handle.net/2027.42/149695Test; Cancer; Thway K, Robertson D, Jones RL, et al. Endosialin expression in soft tissue sarcoma as a potential marker of undifferentiated mesenchymal cells. Br J Cancer. 2016; 115: 473 ‐ 479.; Rouleau C, Smale R, Fu YS, et al. Endosialin is expressed in high grade and advanced sarcomas: evidence from clinical specimens and preclinical modeling. Int J Oncol. 2011; 39: 73 ‐ 89.; Nanda A, Karim B, Peng Z, et al. Tumor endothelial marker 1 (Tem1) functions in the growth and progression of abdominal tumors. Proc Natl Acad Sci U S A. 2006; 103: 3351 ‐ 3356.; Noujaim J, Thway K, Sheri A, et al. Histology‐driven therapy: the importance of diagnostic accuracy in guiding systemic therapy of soft tissue tumors. Int J Surg Pathol. 2016; 1: 5 ‐ 15.; Rouleau C, Curiel M, Weber W, et al. Endosialin protein expression and therapeutic target potential in human solid tumors: sarcoma versus carcinoma. Clin Cancer Res. 2008; 14: 7223 ‐ 7236.; Tomkowicz B, Rybinski K, Sebeck D, et al. Endosialin/TEM‐1/CD248 regulates pericyte proliferation through PDGF receptor signaling. Cancer Biol Ther. 2010; 11: 908 ‐ 915.; Hensley ML, Blessing JA, Mannel R, Rose PG. Fixed‐dose rate gemcitabine plus docetaxel as first‐line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial. Gynecol Oncol. 2008; 109: 329 ‐ 334.; Berry SM, Broglio KR, Groshen S, Berry DA. Bayesian hierarchical modeling of patient subpopulations: efficient designs of phase II oncology clinical trials. Clin Trials. 2013; 10: 720 ‐ 734.; Hollander M, Wolfe DA. Nonparametric Statistical Methods. New York, NY: John Wiley & Sons Inc; 1973.; Brookmeyer R, Crowley J. A confidence interval for the median survival time. Biometrics. 1982; 38: 29 ‐ 41.; Diaz LA, Coughlin CM, Weil SC, et al. A first‐in‐human phase 1 study of MORAb‐004, a monoclonal antibody to endosialin in patients with advanced solid tumors. Clin Cancer Res. 2015; 21: 1281 ‐ 1288.; O’Shannessy DJ, Smith MF, Somers EB, et al. Novel antibody probes for the characterization of endosialin/TEM‐1. Oncotarget. 2016; 7: 69420 ‐ 69435.; O’Shannessy DJ, Dai H, Mitchell M, et al. Endosialin and associated protein expression in soft tissue sarcomas: a potential target for anti‐endosialin therapeutic strategies. Sarcoma. 2016; 2016: 5213628. doi:10.1155/2016/5213628; Maki RG, Wathen JK, Patel SR, et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of Sarcoma Alliance for Research Through Collaboration Study 002. J Clin Oncol. 2007; 25: 2755 ‐ 2763.; Rybinski K, Imtiyaz HZ, Mittica B, et al. Targeting endosialin/CD248 through antibody‐mediated internalization results in impaired pericyte maturation and dysfunctional tumor microvasculature. Oncotarget. 2015; 6: 25429 ‐ 25440.; Rouleau C, Gianolio DA, Smale R, et al. Anti‐endosialin antibody–drug conjugate: potential in sarcoma and other malignancies. Mol Cancer Ther. 2015; 14: 2081 ‐ 2089.; Dickson MA, D’Adamo DR, Keohan ML, et al. Phase II trial of gemcitabine and docetaxel with bevacizumab in soft tissue sarcoma. Sarcoma. 2015; 2015: 532478.; Hensley ML, Blessing JA, Degeest K, et al. Fixed‐dose rate gemcitabine plus docetaxel as second‐line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial. Gynecol Oncol. 2008; 109: 323 ‐ 328.

الإتاحة: https://doi.org/10.1002/cncr.32084Test
https://doi.org/10.1155/2016/5213628Test
http://hdl.handle.net/2027.42/149695Test

المؤلفون: D’Angelo, Sandra P., Hamid, Omid A., Tarhini, Ahmad, Schadendorf, Dirk, Chmielowski, Bartosz, Collichio, Frances A., Pavlick, Anna C., Lewis, Karl D., Weil, Susan C., Heyburn, John, Schweizer, Charles, O’Shannessy, Daniel J., Carvajal, Richard D.

المصدر: Investigational New Drugs; Feb2018, Vol. 36 Issue 1, p103-113, 11p

مصطلحات موضوعية: THERAPEUTIC use of monoclonal antibodies, BIOMARKERS, CONFIDENCE intervals, CLINICAL drug trials, FATIGUE (Physiology), HEADACHE, MELANOMA, METASTASIS, MONOCLONAL antibodies, NAUSEA, NEOVASCULARIZATION, DISEASE progression, DESCRIPTIVE statistics